Xin Lang Cai Jing·2025-11-28 03:04Group 1 - The core viewpoint of the news highlights the financial performance and market activity of Spring Medical, indicating a decline in stock price and notable financing activities on November 27 [1] - On November 27, Spring Medical's stock price fell by 0.69%, with a trading volume of 30.73 million yuan. The financing buy-in amount was 3.88 million yuan, while the financing repayment was 4.75 million yuan, resulting in a net financing buy of -0.87 million yuan [1] - As of November 27, the total margin balance for Spring Medical was 39.66 million yuan, accounting for 0.56% of its market capitalization, which is above the 80th percentile level over the past year, indicating a high level of financing [1] Group 2 - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, with a primary focus on joint prosthetics and spinal implants [2] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. Its products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [2] - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Group 3 - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of Spring Medical included new entrants such as Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund A, holding 2.96 million shares and 2.83 million shares respectively [3] - The eighth largest circulating shareholder, Ping An Low Carbon Economy Mixed Fund A, reduced its holdings by 1.67 million shares, while Southern Medicine Health Flexible Allocation Mixed Fund A exited the top ten circulating shareholders list [3]